CATIE Forum logo

Are you involved in the response to HIV and hepatitis C?

Forum 2015 banner

Transforming our practice: New knowledge, new strategies
Thursday, November 23 to Friday, November 24, 2017
Toronto, ON



Please note: The Forum program is subject to change.

Day One: Thursday, November 23


Registration and continental breakfast


Forum opening and welcome


Concrete Actions to Address STBBIs in Canada

This session will provide an overview of the HIV and hepatitis C targets outlined in the UNAIDS 90-90-90 strategy and the WHO Global Health Sector Strategy on Viral Hepatitis, which we must reach globally to end these epidemics by 2030. Canada has committed to reaching these targets; this session will include discussion of the implications of these commitments and mechanisms required to reach these goals successfully.


Radical acceleration in HIV treatment and prevention science: ending HIV by 2030

Major research advances in HIV treatment and prevention science continuously and conclusively demonstrate the power of antiretroviral medication in significantly improving health and preventing HIV.

To fully realize the benefits of this new research, people living with HIV must know their status, be linked to care, and engage in treatment over the long-term. Other key services may be required to ensure success.  Likewise, people who are negative but at ongoing risk need to be linked to PrEP, STBBI services, and other key programs to reduce their risk.

This session will provide information on these scientific advances and focus on how this new knowledge has chanced practice in prevention, testing, treatment, and linkages across services.


  • Isaac Bogoch, Toronto Western Hospital, Toronto, ON
  • Miranda Compton, Vancouver Coastal Health, Vancouver, BC

Other speakers to be confirmed.




What it will take: Eliminating HCV by 2030

Hepatitis C cure, something now made possible through new HCV treatments that are shorter, more tolerable and much more effective than previous treatments, has the potential to revolutionize the HCV landscape. This knowledge has stimulated policy planners, public health officials and researchers to envision hepatitis C elimination.

While access to new HCV treatments is opening up across Canada, barriers exist to engaging in testing, treatment, and linkage to important services that help people stay in care. Harm reduction programming is also essential.

This session will provide information on hepatitis C-related scientific advances and focus on what is required to eliminate HCV for all people affected.


Lisa Barrett, Dalhousie University, Halifax, NS

Other speakers to be confirmed.




Harnessing new HIV and hepatitis C testing technologies and approaches

There is a need to step up HIV and hepatitis C testing efforts to reach the undiagnosed in Canada. This plenary will focus on information about the gaps in the cascade to diagnosis; suggest that we need to be doing things differently; and share the promising nature of community-clinical strategies for improving efforts to reach the HIV and HCV undiagnosed in Canada.


Mark Gilbert, BC Centre for Disease Control, Vancouver, BC


The shifting landscape of hepatitis C: responding to the needs of people affected

The implications of new HCV treatments for individuals and service provision will be explored and key experts with lived experience of hepatitis C will be invited to share knowledge about how to engage people in HCV treatment, support people while on treatment, and what is useful/needed post-cure. It will also shed light on barriers and facilitators to treatment.

Speakers to be confirmed.




Concurrent Sessions: Focus on programming

This series of break-out sessions will focus on program planning and delivery related to PrEP as a part of combination prevention, the role of harm reduction in our efforts to address HIV and hepatitis C, HIV and HCV testing strategies, peer health navigation, and integrated models of care.

Session 1: Increasing access to PrEP for gay, bi, and other men who have sex with men through community-based programming

Session 2: Addressing hepatitis C drivers and barriers: The role of harm reduction in addressing HCV among people who use drugs 

Session 3: HIV Peer Health Navigation

Session 4: Expanding access to community-based HCV and HIV testing and linkage: The role of Dried Blood Spot

Session 5: How the National HIV Stigma Index can Influence our practice and programs


5:15 – 7:15

Networking reception

Day Two: Friday, November 24


Registration and Continental Breakfast


CATIE Annual General Meeting




HIV stigma through the lens of Undetectable = Untransmittable

While the scientific realities of living with HIV have fundamentally changed given our new knowledge in HIV treatment and prevention, HIV stigma remains, and is an important community and public health issue that needs to be addressed. This session will focus on HIV prevention science, concepts such as “Undetectable = Untransmittable” and HIV stigma, and provide commentary on action to create enabling legal environments and stigma-free public health and clinical practices for prevention, testing, treatment, care, and support.


  • Bruce Richman, Prevention Access Campaign, New York, NY
  • Francisco Ibanez-Carrasco, Ontario HIV Treatment Network, Toronto, ON

Speakers to be confirmed.




Concurrent Sessions: Focus on programming

This series of break-out sessions will focus on program planning and delivery related to HIV communications in the era of U=U, supervised injection services, programming in the era of new HCV treatments, and linkage to care programming.

Session 1:  Approaches to changing the narrative of HIV communications in an era of U=U

Session 2:  HIV prevention and treatment science: new considerations for infant feeding?

Session 3: Supervised consumption sites:  implementation and operation

Session 4: HIV self-testing: are we ready?

Session 5: Hepatitis C Treatment Access: Expanding and diversifying HCV Treatment Models




Structural stigma and reaching our HIV and HCV targets


  • Jody Jollimore, Community Based Research Centre, Vancouver, BC
  • Alexandra King, Lu’Ma Medical Centre, Vancouver, BC
  • LaRon Nelson, Ontario HIV Treatment Network, Toronto, ON




Concurrent sessions

This series of three separate break-out sessions will narrow in on some specific priorities and program models that relate to African, Caribbean and Black communities; gay, bisexual, two spirit and other men who have sex with men; Indigenous communities; people who use drugs; and newcomer communitiesand people living with HIV. While specific populations form the basis of these sessions, intersectionality will be an important focus. More specific information on each session to come.




The role of the HIV and hepatitis C response in the opioid overdose crisis

This session will increase understanding of the opioid overdose crisis in Canada, its roots and its impact on people living with HIV and affected by hepatitis C. It will challenge participants to consider their role, as HIV and HCV service providers, in addressing this crisis.


  • Jordan Westfall, Canadian Association of People Who Use Drugs (CAPUD), BC
  • Mark Tyndall, BC Centre for Disease Control, BC
  • Yvette Perrault, AIDS Bereavement and Resiliency Project, ON


Thank You and closing